This study investigates metastatic pancreatic ductal adenocarcinoma. It evaluates the potential benefits of combining radiation therapy with immune checkpoint inhibitors.
The study focuses on assessing the safety and effectiveness of this combination treatment. It evaluates how well these therapies work together in patients with this condition.
- Who can participate: Adults 18 years and older with a confirmed diagnosis of pancreatic ductal adenocarcinoma may participate. Eligibility includes measurable disease and a life expectancy of at least 3 months.
- Study details: Participants will receive a combination of radiation therapy and immune checkpoint inhibitors. Some may receive a placebo, an inactive substance resembling the investigational medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand